Jones Financial Companies Lllp Acquires 817 Shares of Guardant Health, Inc. (NASDAQ:GH)

Jones Financial Companies Lllp boosted its holdings in Guardant Health, Inc. (NASDAQ:GH) by 43.5% in the 4th quarter, HoldingsChannel reports. The firm owned 2,696 shares of the company’s stock after purchasing an additional 817 shares during the quarter. Jones Financial Companies Lllp’s holdings in Guardant Health were worth $82,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Wellington Management Group LLP boosted its position in shares of Guardant Health by 188.6% during the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company’s stock valued at $232,325,000 after acquiring an additional 6,618,785 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Guardant Health by 1,282.5% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company’s stock valued at $28,128,000 after acquiring an additional 1,137,482 shares during the last quarter. Erste Asset Management GmbH bought a new position in shares of Guardant Health during the 3rd quarter valued at approximately $21,389,000. Lord Abbett & CO. LLC bought a new position in shares of Guardant Health during the 3rd quarter valued at approximately $15,624,000. Finally, Two Sigma Advisers LP boosted its position in shares of Guardant Health by 52.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,177,300 shares of the company’s stock valued at $27,007,000 after acquiring an additional 406,500 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. The Goldman Sachs Group increased their target price on Guardant Health from $49.00 to $56.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Raymond James restated an “outperform” rating and issued a $59.00 price target (up from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Piper Sandler raised their price target on Guardant Health from $34.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Scotiabank raised their price target on Guardant Health from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Monday, February 24th. Finally, JPMorgan Chase & Co. raised their price target on Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Twenty research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $48.40.

Guardant Health Stock Up 5.5 %

GH stock opened at $42.89 on Monday. The firm has a market cap of $5.29 billion, a price-to-earnings ratio of -12.05 and a beta of 1.50. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $50.89. The business’s fifty day simple moving average is $43.01 and its two-hundred day simple moving average is $32.94.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to analysts’ expectations of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Research analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.